At a glance
ClinicalIndex Comparison RecordPhase 2Active· 101 enrolled
Drug / intervention
Pembrolizumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Pembrolizumab in Central Nervous System Metastases From Multiple Histologies
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab, MRI, and 2 other interventions for Brain Metastases. Active but no longer recruiting, targeting 101 participants across 2 sites.
Detailed Summary
This research study is studying Pembrolizumab as a possible treatment for this diagnosis for metastases in the central nervous system (brain and spinal cord).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Metastases
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2Active
201720182019202020212022202320242025202620272028
First PostedSep 2016
Enrollment StartOct 2016
TodayJul 2026
Primary CompletionJun 2027
Study CompletionJun 2028
First PostedSep 1, 2016
Enrollment StartOct 1, 2016
Primary CompletionJun 1, 2027
Study CompletionJun 1, 2028
TodayJul 2, 2026
Enrollment to primary: 10.7 yearsPosted 9.8 years agoPrimary completion in 11 months
Interventions
Pembrolizumabdrug
MRIradiation
PET/CTradiation
Stereotactic Radiosurgeryprocedure